Drug intelligence / Profile preview

DWC202206

Development stage: Phase 3
Modality: Small Molecules
Administration: Oral (assumed Based On Typical Administration For Hypertension/hyperlipidemia Drugs; Not Explicitly Stated)

Overview

DWC202206 is an investigational drug being evaluated in clinical trials for the treatment of patients with concomitant hypertension and hyperlipidemia. The drug is studied in combination with another investigational agent, DWC202207, as part of a randomized, double-blind, multicenter clinical trial. The primary endpoints include changes in mean sitting systolic blood pressure (MSSBP) and low-density lipoprotein cholesterol (LDL-C) from baseline[2]. No specific mechanism of action or detailed pharmacological class has been publicly disclosed for DWC202206.

Beyond the preview

Go deeper on DWC202206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202206.

Explore the full profile